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Abstract
Introduction: Product adherence and its measurement have emerged as a critical challenge in the evaluation of new HIV
prevention technologies. Long-acting ARV-based vaginal rings may simplify use instructions and require less user behaviour,
thereby facilitating adherence. One ARV-based ring is in efficacy trials and others, including multipurpose rings, are in the
pipeline. Participant motivations, counselling support and measurement challenges during ring trials must still be addressed. In
previous HIV prevention trials, this has been done largely using descriptive and post-hoc methods that are highly variable and
minimally evaluated. We outline an interdisciplinary framework for systematically investigating promising strategies to support
product uptake and adherence, and to measure adherence in the context of randomized, blinded clinical trials.
Discussion: The interdisciplinary framework highlights the dual use of adherence measurement (i.e. to provide feedback during
trial implementation and to inform interpretation of trial findings) and underscores the complex pathways that connect
measurement, adherence support and enacted adherence behaviour. Three inter-related approaches are highlighted: 1)
adherence support  sequential efforts to define motivators of study product adherence and to develop, test, refine and
evaluate adherence support messages; 2) self-reported psychometric measures  creation of valid and generalizable measures
based in easily administered scales that capture vaginal ring use with improved predictive ability at screening, baseline and
follow-up that better engage participants in reporting adherence; and 3) more objective measurement of adherence  real-time
adherence monitoring and cumulative measurement to correlate adherence with overall product effectiveness through
innovative designs, models and prototypes using electronic and biometric technologies to detect ring insertion and/or removal
or expulsion. Coordinating research along these three pathways will result in a comprehensive approach to product adherence
within clinical trials.
Conclusions: Better measurement of adherence will not, by itself, ensure that future effectiveness trials will be able to address
the most basic question: if the product is used per instructions, will it prevent HIV transmission? The challenges to adherence
measurement must be addressed as one component of a more integrated system that has as its central focus adherence as a
behaviour emerging from the social context of the user.
Keywords: vaginal ring; acceptability; adherence; clinical trial research; HIV prevention; measurement.
Received 21 March 2014; Revised 29 June 2014; Accepted 22 July 2014; Published 8 September 2014
Copyright: – 2014 MacQueen KM et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Introduction
In July 2010, the CAPRISA 004 clinical trial of tenofovir 1% gel
demonstrated that an ARV-based vaginal gel could prevent
acquisition of HIV [1]. Subsequently, results from the iPrEX,
Partners PrEP, TDF2 and Bangkok Tenofovir trials of oral ARV
dosing further bolstered confidence in ARV-based prevention
[25]. In each of these trials, sub-analyses indicated that poor
adherence to the prescribed dosing regimen reduced efficacy.
The importance of adherence to product use instructions
was underscored by results from the VOICE and FEM-PrEP
trials, where poor adherence to vaginal (VOICE) and oral
(VOICE and FEM-PrEP) dosing regimens resulted in an inability
to determine effectiveness [6,7].
The delivery of microbicides through vaginal rings is
perceived by some as a way to achieve better adherence,
in part because rings have the potential to simplify the
behavioural requirements for use. A number of long-acting
ARV-based and multi-purpose prevention rings are in devel-
opment.Two phase 3 clinical trials are now underway to assess
the efficacy of a 28-day vaginal ring containing the antire-
troviral drug dapivirine to reduce HIV transmission among
African women [8]. Other rings in development include
CONRAD’s 90-day ring that contains both tenofovir and
a contraceptive; the International Partnership for Microbicide’s
(IPM) dapivirine ring with or without a contraceptive added
that would be effective for 30 days and potentially up to 6090
days; the Population Council’s 90-day ring containingMIV-150,
zinc acetate and carrageenan, with or without a contraceptive,
designed to protect against HIV, herpes simplex virus type-2
and human papillomavirus (Barbara Friedland, personal
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communication, 2014); and Merck’s project to develop their
ethylene vinyl acetate copolymer contraceptive ring as a
method for also delivering ARVs. It is anticipated that over
the next three years, multiple products will move from
preclinical to clinical testing of safety and pharmacokinetics
during use ranging from 30 days to 12 months.
Social science research with participants in trials of micro-
bicides and PrEP indicate that a wide array of factors may
potentially influence adherence. For example, lack of under-
standing about clinical research practices (e.g. how biological
specimens will be used) [9], concerns about product safety
[10] and distrust of the motivations of researchers and trial
sponsors (e.g. motivated by negative values such as greed and
racism) [9,11,12] are frequently described for HIV prevention
research participants and communities. For women, decisions
about whether and what to disclose to male partners about
product use and research participation reflect culturally
regulated gender dynamics that can either generate support
or create obstacles for a woman’s decision to participate in
a trial and adhere to product use [10,1317]. There is also
increasing recognition of the fact that the on-going and
intensive level of interaction among participants in the
research clinic waiting room and between participants and
research staff foster the emergence of a research culture that
may exacerbate or mitigate these other challenges [10].
Research conducted by IPM in preparation for phase 3 trials
of the 30-day dapivirine ring found that women reported
removal or expulsion of the ring between study visits at fre-
quencies ranging from 4 to 18% of participants over varying
time frames [18,19]. The most common reasons cited for ring
removal were menses, periodic cleaning and expulsion during
urination or defecation. Currently, self-report is the primary
method for estimating the number of hours or days that a
removed or expelled ring remains outside the vagina before it
(or a new ring) is inserted. Although self-reported adherence
has been shown to over-estimate product use to varying
degrees in ARV-based HIV prevention trials, collecting infor-
mation on reasons for non-adherence and participants’ ex-
periences with product use more generally is essential to
providing effective counselling and support for proper use
of all such products, including vaginal rings. Recognition of
adherence challenges is necessary but not sufficient to ensure
that participants receive adequate support for adherence at
the level needed to evaluate product effectiveness. Also
important are motivations for adherence within the context
of a clinical trial. Most research on adherence outcomes has
focused on the treatment context, where the goal is to
maximize health benefits for clients. In the trial context, the
health benefits of product use are unclear and may be non-
existent, especially if there is randomization to a placebo arm.
There is also greater ambiguity about the potential risks than is
normally the case with approved medications. These unique
clinical trial elements must be considered in optimizing clinical
trial adherence to ring use. Additional consideration must be
given to how the clinical trial elements are situated relative
to the social context of the trial participants, for example,
how the motivations of researchers are understood in the
community.
Because vaginal rings can be inserted and removed by the
user, direct observation of enacted adherence, that is, the
actual act of using the product over time, is not feasible. In
this regard, the adherence measurement challenges for rings
are similar to those faced in identifying a valid, reliable and
accurate measure of microbicide adherence with respect to
other drug delivery systems, which has been elusive [20].
Proxy measures of adherence for microbicides specifically,
and for PrEP more generally, have ranged from self-reported
counts of use/non-use to measurement of drug concentra-
tion in the blood and vaginal fluids. All proxy measures have
strengths and weaknesses [21]. For example, in the case of
vaginal rings, the wide intra-individual variability in drug
blood levels during use creates challenges for accurately as-
sessing how long an ARV-based ring has been inserted or if it
has been removed or expelled and reinserted [22]. Efforts are
underway to identify biomarkers of adherence, for example,
measurement of residual drug in rings, the quantification of
biofilm on the surface of vaginal rings to assess duration of
insertion and assessment of plasma drug levels aggregated by
site. Nonetheless, adherence measurement remains depen-
dent, at least in part, on self-report, which is known to be
affected by social desirability biases and cognitive limits on
recall [23,24].
No single approach to measuring ring adherence will be
adequate to provide the level of detail needed to 1) monitor
adherence in real time to target participants for focused dis-
cussions around product use, 2) allow for statistical inferences
about effectiveness while controlling for adherence and
3) inform planning for adherence assessments during pro-
grammatic implementation of effective products. Increasingly,
researchers are advocating for use of several adherence
measures that can be triangulated [25,26].
While considerable innovation is emerging to provide
adherence support and develop more objective measures,
approaches have been largely specific to a particular study or
study-site. Furthermore, the adherence support procedures
used to date in microbicide or PrEP trials have been derived
from theory and practice established mainly in the treatment
context, with no evaluative piloting for the experimental
prevention research context. In the CAPRISA 004, iPrEX and
VOICE trials adherence support procedures underwent mod-
ification after trials were well underway [27,28]. Empirical
data on the fidelity of research teams to adherence support
guidelines is limited, further undermining efforts to under-
stand the effectiveness of a given adherence support
approach. Biometric measures such as drug levels have simi-
larly undergone continual refinement in the context of the
very trials where those measures have been used to evaluate
adherence. Innovative approaches sometimes have difficulty
getting traction in clinical trials, due to concerns about their
impact on trial implementation in the absence of pilot data.
Discussion
Developing an interdisciplinary framework
An interdisciplinary framework is needed to move past the
current ad hoc approach and integrate the various dimensions
of adherence assessments without burdening or detracting
from on-going product development or trial implementation.
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Figure 1 describes the key components of such a framework
for understanding, measuring and supporting ring adherence.
This framework highlights the dual use of adherence mea-
surement (i.e. to provide feedback during trial implementa-
tion and to inform interpretation of trial findings) and
underscores the complex pathways that connect measure-
ment, adherence support and enacted adherence behaviour.
Adherence support process
Secondary analysis of data from the CAPRISA 004 trial suggests
that use of a theory-driven approach to support adherence
to product use instructions can be effective. Midway through
the CAPRISA 004 trial the investigators revised their adher-
ence support approach to a counselling package based on
motivational interviewing, referred to as Adherence Support
Program (ASP). Findings indicate that implementation of ASP
was associated with an increase in the proportion of women
reporting high adherence, an increase in detectable tenofovir
levels and an increase in the estimate of product effectiveness
[29]. Similarly, the Uganda Partners PrEP site conducted an
ancillary adherence counselling intervention study with a
subset of participants. The intervention was adapted from an
evidence-based HIV treatment adherence intervention called
Lifesteps [30] that included cognitive-behavioural, motiva-
tional interviewing, and problem-solving techniques and
significantly increased adherence as measured by unan-
nounced pill counts [31].
In the iPrEX PrEP trial among MSM, which also demon-
strated product effectiveness, a different but somewhat
related approach was developed called next step counselling
(NSC). NSC was designed to promote open discussions about
product use and to build motivation and positive regard for
the use of an unproven product (or potentially a placebo
product) within a clinical trial [32]. In conjunction with NSC,
a neutral assessment (NA) approach was also implemented
where rates of product use were collected by non-counselling
team members who were trained to intentionally remove
judgment and negative consequences (e.g. extensive follow-
up, probing or additional procedures) for reporting product
non-use. The combined NSC/NA approach subsequently formed
the basis for adherence support procedures called VASP
(VOICE adherence strengthening program) used in the latter
half of the VOICE trial. Neither trial had a comparison arm by
which to evaluate the combined approach. However, unlike
the CAPRISA 004 and Uganda Partners PrEP findings, mid-trial
adoption of VASP did not appear to increase adherence when
individual adherence was examined pre- and post-VASP im-
plementation. A NSC/NA type of approach was used in the
early part of FACTS 001 (an on-going follow-on phase 3 trial
to replicate CAPRISA 004), which was subsequently switched
to using the ASP approach. The IPM and MTN trials currently
Figure 1. An integrated framework for adherence support and measurement in clinical trials of ARV-based vaginal rings for HIV
prevention.
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assessing IPM’s 28-day dapivirine vaginal ring draw on a
variety of adherence support strategies. The MTN study uses
a VASP-style approach, called Adherence Counseling Educa-
tion (ACE) and a number of small group-focused discussions
and activities. Common elements across all of the ARV-based
trials described above include aspects of motivational in-
terviewing and client centred models originally developed
outside the research context; some also include use of
product returns, self-report or biomarker (drug level) mea-
sures of product non-use to target adherence counselling
with participants.
While current efforts to address the adherence support
challenges in real-time with on-going clinical trials are theory-
based and draw on behavioural science methods, none of the
approaches used in blinded biomedical randomized con-
trolled trials of HIV prevention have been evaluated rigor-
ously for that context. The motivational interviewing and
client-centred counselling approaches used in these trials
were derived from models largely developed with U.S. pop-
ulations and focused on counselling intended to engage
clients in the dynamics of change, that is, moving from a
behaviour or set of behaviours that are recognized as costly/
unhealthy to ones that are beneficial/healthy [33]. Counsel-
lors sought to promote investment in change, avoiding overt
instruction or persuasion about what clients ‘‘should’’ do.
Instead, counsellors respected clients’ reasons not to change,
provided a safe place for full expression of this resistance to
change, and facilitated genuine development of an apprecia-
tion and desire for an alternative to current behaviour that
maximized values and perceived benefits from a client’s
perspective.
The reality of clinical trial research limits implementation
of full motivational interviewing principles. For example,
while participants in randomized controlled trials have auto-
nomy with regard to deciding whether to enrol or whether
to comply with all study requirements, they lack autonomy
to actively choose the intervention to be administered 
a component of choice that is core to the MI approach.
Similarly, given the critical importance of protocol compliance
for successful trial implementation, it is unlikely that research
staff can maintain genuine appreciation for a participant’s
right not to adopt the trial-desired behaviour. Finally, the
primary motivational basis behind MI is undermined by the
potential lack of a direct (or any) health benefit accruing to
the participant as a result of adopting the clinically-desired
adherence behaviour.
In contrast to motivational interviewing-based approaches,
compliance-oriented approaches rely on overt persuasion,
use of external reinforcements or the threat of negative con-
sequences to encourage clients to adopt a behaviour judged
by an external expert to be ‘‘better for you.’’ However, the use
of pure persuasion can be alienating and could create negative
feelings towards product use and trial participation, which
could further deteriorate motivation to report on product
non-use in the clinical research setting. The use of motiva-
tional interviewing-based engagement with participants, with
its valuing of genuine discourse and attempt to balance power
between researchers and participants is arguably a better fit
with the participatory kinds of engagement reflective of
current standards for HIV prevention research practice [34].
Effective support for study product use in blinded HIV
prevention trials requires a theory-based, informed approach
that meets the specific needs of both trial participants and
the trial itself. Such a participant-centred approach would
leverage respect for autonomy, as classically defined for
human research protections [35,36], while opening a dialog
to identify, develop and foster personal investment in the
objectives of the prevention trial. It would acknowledge, and
then work with the uncertainty of a direct health benefit and
the unknown health risks accruing to the participant as a
result of adherence in the experimental context of a pre-
vention trial. It would also explicitly recognize the cultural
and social dynamics that enter into a person’s motivations
to enrol in a trial, continue active engagement, take up
product use as assigned and adhere to study requirements
as requested. Unique to a participant-centred approach, the
intervention focus would be the participants’ motivation
towards and skills in achieving full engagement with the re-
search goals of the study rather than specifically on product
use, per se. Persistent, as-recommended product use would
be one of several desired outcomes of personal engagement
in the study.
Adherence support fidelity
Anecdotal evidence suggests that fidelity to adherence
support protocols by trial staff may be a significant but un-
measured factor in participant adherence to instructions for
product use. The importance of fidelity was underscored in a
recent assessment of MI to support ARV treatment adherence
in South Africa [37]. Yet fidelity measures are rarely included
in HIV prevention trials. Considerable attention has been
placed on the failure of women to follow product use
instructions in the FEM-PrEP and VOICE trials but very little
has been focused on whether those providing the instructions
and adherence support were doing so in compliance with
the standards and procedures developed for the trials. In the
absence of fidelity measures it is impossible to determine the
relative contributions of participant motivation, adherence
support system design and provider implementation. An
effective adherence support process will not ensure adequate
levels of adherence if it is poorly implemented.
Adherence psychometrics
Despite shortcomings, the assessment of self-reported ad-
herence remains a standard component of trials because it is
inexpensive, relatively non-invasive and allows for immediate
feedback [21]. Methods to improve validity and reliability of
self-reported adherence measures have largely focused on
mode of data collection (e.g. use of ACASI). However, there
has been a lack of support for development of psychometric
measures similar to those long used to assess treatment non-
compliance [38,39]. Psychometrically validated scales are
composed of multiple items in the form of questions or
statements that, when combined, measure a more complex
concept that may not be directly observable [4042]. As such,
they may better assess the multiple factors likely to contribute
to non-adherence.
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Drawing on behavioural theory and existing social and
behavioural research on acceptability and adherence, it
should be feasible to identify a multidimensional set of items
that assess adherence to products in the HIV prevention
pipeline. The process for developing such psychometric
measures is fairly straightforward. The first step is to identify
relevant conceptual domains that influence ring adherence,
developing specific items that adequately represent each
domain. Both the published literature and unpublished
qualitative data may be consulted to determine potential
domains, such as product-related attitudes (i.e. perceived
benefits and barriers to ring use), motivations for product use
within a clinical trial setting and perceived self-efficacy to use
a ring as instructed, as well as barriers potentially associated
with non-adherence (i.e. low levels of knowledge, social
stigma associated with product use, male partner concerns,
domestic violence, lack of mobility.) Content validity  the
degree to which the domains and draft items represent the
underlying dimensions of vaginal ring adherence behaviour
within a clinical trial context  would be assessed in part
through review and feedback by a panel of behavioural and
social researchers, cultural experts and/or clinicians with
expertise in HIV prevention adherence. Both the content,
sequence and wording of draft items, as well as the overall
framing and instructions for scale administration, must then
be evaluated in a small number of culturally diverse sites,
using standard cognitive interviewing techniques and/or focus
group discussions, to verify that the draft measure includes
relevant content and that individual items are salient, well
understood and easily rated by participants similar to those
who might take part in vaginal ring trials.
After the draft scale items are refined, they are incorpo-
rated into a survey that also includes measures of behavi-
ours or attitudes that are hypothesized to predict or affect
adherence directly or indirectly. The survey is administered to
women in one or more cultural settings who are current or
former trial product users. Exploratory and confirmatory
factor analysis techniques are applied to determine the final
structure and content of the adherence scale, and the the-
oretical associations between adherence as measured by
the scale and other factors/variables are explored. Once the
psychometric properties of the scale measure is confirmed,
opportunities to assess the predictive value of the adherence
scale can then be sought, for example, by examining how
well the scale score correlates with biometric indicators of
product use.
A validated scale of vaginal ring adherence would poten-
tially have multiple applications within the context of HIV
prevention clinical research. It could support the trial’s eval-
uation of vaginal ring efficacy by providing complementary
evidence on adherence, particularly when biomarker adher-
ence data may be missing or incomplete for some trial par-
ticipants. The use of a composite biomarker-plus-adherence
scale approach was shown to correlate better with viral load
than use of biomarker data alone in one study on HAART
effectiveness [43]. Additionally, given the multidimensional
composition of a vaginal ring adherence scale, it could alert
staff to a participant’s potential issues around adherence at
baseline (if, for example, commitment to correct and con-
tinuous product use ranked low among an individual’s
motivations for trial participation) and/or provide real-time
feedback on barriers or facilitators of use to adherence
support staff over the course of the trial. While the process
of developing adherence psychometrics requires an upfront
investment of time and resources, once a scale is validated it
is a cost-effective tool to adapt and implement across the
applications described above.
Adherence biometrics
There has been considerable attention given to the develop-
ment of biomarkers and biometric measures that rely less on
verbal self-report by participants and provide more direct
measures of events or adherence. Examples include electronic
devices such as MemsCap and WisePill devices for pill storage
and Wisebag for microbicide applicator storage, which allow
electronic tracking of when the storage devices are opened,
ostensibly for use (or, in the case of rings, for storage) of
the product [44,45]. Some biometric approaches may indi-
cate a point-in-time when the product is used, while other
approaches may indicate more cumulative use patterns. For
example, two approaches currently under investigation with
the potential to measure varying durations of ring use include
quantification of ring biofilm (which should increase with
duration of insertion) and of residual drug (which should
decrease with duration of insertion). Other biometric methods
have the potential to indicate ring insertion at a given point
in time. One such approach is the adaptation of an esther
taggant previously tested in vaginal gel to ring technologies
[46]. Another approach with some potential is the use of an
RFID tag that would allow random non-intrusive scanning for
ring insertion. Rather than measuring ring insertion, some
biometric approaches might indicate current or cumulative
ring removal. For example, it might be possible to develop a
cumulative measure of ring exposure to air that could indicate
the proportion of time the ring was removed, or exposure to
water that might indicate removal and washing.
Adherence analytics
To address vaginal ring adherence in the comprehensive way
described above, we need to consider the analytical integra-
tion of the various approaches. As illustrated in Figure 1,
analytic findings from each framework component may
inform other components as well as ensuring that the best
science is used within each component.
Individual elements of comprehensive adherence support
processes should minimally be pretested through use of
cognitive interviewing techniques and piloted using compre-
hension assessments on the part of participants and fidelity
assessments with regard to implementation by research staff
prior to their use in effectiveness trials. Experimental or quasi-
experimental assessments of the comparative effectiveness of
different adherence support system designs would be ideal.
Formative research to develop adherence support can also
inform development of the psychometric measures and
determine acceptability of various biometric measurement
approaches in specific cultural contexts.
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Examples of fidelity measures that should be included in
ARV-based HIV prevention trials include the quality and extent
of staff training in the method, quality and consistency in
implementation, organizational support for implementation,
documentation of practices and adaptation to local and
emergent needs. Use of mobile phones or other technology
may also be helpful in monitoring fidelity as well as adherence
on the part of participants. Here again, formative research
findings will be critical for developing and adapting measures
to specific trials and contexts.
Points of potential interface between psychometric and
biometric measurement and adherence support should be
identified and consciously and overtly considered when de-
signing measures, support strategies and guidelines for
administering each.
Conclusions
After more than two decades of biomedical HIV prevention
effectiveness trials, it is now clear that randomization, blinding
and use of placebo controls cannot mitigate any behavioural
or sociocultural context-specific issues that might arise during
the course of a trial. Rather, behaviours and contexts that drive
adherence are at issue for evaluating effectiveness. Increas-
ingly, researchers are advocating for use of several adherence
measures that can be triangulated [19,38]. Coordinated
research is needed along three pathways to generate com-
plementary measures that can then be triangulated for a
comprehensive picture: 1) psychometrics to improve self-
report measures reflective of behaviour; 2) electronic dispen-
sing or storage options to capture events corresponding to
intended product use or non-use; and 3) biometrics to capture
indications of product ingestion or insertion, as well as fre-
quency or duration of same. Better measurement of adher-
ence will not, by itself, ensure that future effectiveness trials
will be able to address the most basic question: does the
product prevent HIV transmission? The challenges to adher-
ence measurement must be addressed as one component of a
more integrated system that has as its central focus adherence
as a context-driven behaviour.
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